Microcap Adventrx Pharmaceuticals (ANX) shares plummet -56% after the FDA rejects a new...


Microcap Adventrx Pharmaceuticals (ANX) shares plummet -56% after the FDA rejects a new application for the development-stage drug maker's lung-cancer treatment Exelbine. The agency says the authenticity of the drug products used in its pivotal bioequivalence trial could not be verified.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs